Clinical and immunological implications of lymphocyte-activation gene 3 expression in metastatic colorectal cancer

Key Points

• To evaluate the clinical and immunological significance of LAG3 expression in metastatic colorectal cancer (mCRC).
• Analyzed LAG3 expression levels in colorectal cancer samples.
• Examined the role of Galectin-9-TIM-3 signaling in LAG3+CD8+ T cells.
• Proposed combinational immunotherapy strategies based on findings.
• LAG3 expression serves as an independent prognostic biomarker for mCRC.
• Galectin-9-TIM-3 signaling may limit the effectiveness of LAG3 blockade.
• Combinational immunotherapies could enhance treatment outcomes.